Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(±)-trans-ACPD
说明： Group I and II mGlu agonist
化学名： (±)-1-Aminocyclopentane-trans-1,3-dicarboxylic acid
纯度： ≥99% (HPLC)
生物活性 for (±)-trans-ACPD
(±)-trans-ACPD is an equimolecular mixture of (1S,3R)- and (1R,3S)-ACPD. Selective agonist for metabotropic glutamate receptors; active at both group I and group II mGlu receptors (EC50 values are 2, 15, 23 and ~800 μM at mGluR2, mGluR1, mGluR5 and mGluR4 respectively).
(1S,3R)-ACPD and cis-ACPD also available.
技术数据 for (±)-trans-ACPD
| 分子量 | 173.17 |
| 公式 | C7H11NO4 |
| 储存 | Store at RT |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 67684-64-4 |
| PubChem ID | 23789032 |
| InChI Key | DXLSPTHQGVGVTN-NAAZMWONSA-N |
| Smiles | [H][C@@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O.[H][C@]1(CC[C@](N)(C1)C(O)=O)C(O)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for (±)-trans-ACPD
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| water | 5 温和加热 | ||
| 1eq. NaOH | 8.66 | 50 |
制备储备液 for (±)-trans-ACPD
以下数据基于产品分子量 173.17。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 11.55 mL | 57.75 mL | 115.49 mL |
| 2.5 mM | 2.31 mL | 11.55 mL | 23.1 mL |
| 5 mM | 1.15 mL | 5.77 mL | 11.55 mL |
| 25 mM | 0.23 mL | 1.15 mL | 2.31 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for (±)-trans-ACPD
参考文献 for (±)-trans-ACPD
参考文献是支持产品生物活性的出版物。
Conti et al (2002) Synthesis and pharmacology of 3-hydroxy-Δ2-isoxazoline-cyclopentance analogues of glutamic acid Farmaco 57 889 PMID: 12484537
Knopfel et al (1995) Metabotropic glutamate receptors: novel targets for drug development. J.Med.Chem. 38 1417 PMID: 7738999
Nakanishi (1992) Molecular diversity of glutamate receptors and implications for brain functions. Science 258 597 PMID: 1329206
Pin and Duvoisin (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34 1 PMID: 7623957
If you know of a relevant reference for (±)-trans-ACPD, please let us know.
按标靶查看相关产品
关键词: trans-ACPD, trans-ACPD supplier, Group, II, group, I, mGlur, agonists, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, mGlu1, mGlu5, mGluR1, mGluR5, tacpd, trans-acpd, (Metabotropic), 0187, Tocris Bioscience
7 篇 (±)-trans-ACPD 的引用文献
引用文献是使用了 Tocris 产品的出版物。 (±)-trans-ACPD 的部分引用包括：
Coulon et al (2011) Activity Modes in Thalamocortical Relay Neurons are Modulated by G(q)/G(11) Family G-proteins - Serotonergic and Glutamatergic Signaling. Front Cell Neurosci 4 132 PMID: 21267426
Rojas et al (2013) Activation of group I metabotropic glutamate receptors potentiates heteromeric kainate receptors. Mol Pharmacol 83 106 PMID: 23066089
Newman (2005) Calcium increases in retinal glial cells evoked by light-induced neuronal activity. J Neurosci 25 5502 PMID: 15944378
Ying and Goldstein (2005) PropF. suppresses synaptic responsiveness of somatosensory relay neurons to excitatory input by potentiating GABA(A) receptor chloride channels. Mol Pain 1 2 PMID: 15813991
Young and Sun (2007) Long-term modifications in the strength of excitatory associative inputs in the piriform cortex. Chem Senses 32 783 PMID: 17634388
Fujino and Oertel (2003) Bidirectional synaptic plasticity in the cerebellum-like mammalian dorsal cochlear nucleus. Proc Natl Acad Sci U S A 100 265 PMID: 12486245
Nishi et al (2003) Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Proc Natl Acad Sci U S A 100 1322 PMID: 12538871
您是否知道使用了 Tocris (±)-trans-ACPD 的优秀论文？ 请告知我们.
(±)-trans-ACPD 的评论
平均评分: 5 (Based on 1 Review.)
Have you used (±)-trans-ACPD?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
An mGluR agonist.
By
Anonymous on 02/21/2018
分析类型： Ex Vivo
种属： Rat
trans-ACPD is mGluR agonist (Group I and II). We used at 100 microM in rat brain slices. It increases intracellular Ca2+ in astrocytes.
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.